Literature DB >> 1414682

Differences in proinflammatory activity of several immunomodulatory derivatives of muramyl dipeptide (MDP) with special reference to the mechanism of the MDP effects.

Z Zídek1.   

Abstract

Immunomodulatory agents, muramyl dipeptide (MDP) and several of its analogues, i.e. adamantylamide dipeptide, murametide, murabutide and their glucosaminylated derivatives, were tested for edemagenic activity in rats. Given systemically in aqueous solutions, only MDP and glucosaminylated MDP, at the dose of 3 mg/kg (s.c. or p.o.), were found to produce edematous swelling of the paws. Local (intra-pad) application of MDP was more effective than the systemic one. Supernatants of macrophages, in vitro cultured in presence of MDP, caused the swelling as well. The edema was of a transient nature. After reaching the maximum severity (about 6 h after injection of MDP solution or 1 h after macrophage supernatants), it was subsiding and disappeared completely within approximately 6 days after cessation of the treatment. It was found that this type of rat paw edema is probably a prostaglandin-dependent consequence of macrophage activation. Hypotheses on the involvement of immunoregulatory cytokines, and possible chemical structure-inflammatory activity relationships have been suggested.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1414682     DOI: 10.1007/bf01991241

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  32 in total

1.  Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production in vivo.

Authors:  M R Shalaby; A Waage; L Aarden; T Espevik
Journal:  Clin Immunol Immunopathol       Date:  1989-12

2.  The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors.

Authors:  I C Kettelhut; W Fiers; A L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

3.  Induction of human interleukin 1 mRNA measured by collagenase- and prostaglandin E2-stimulating activity in rheumatoid synovial cells.

Authors:  J M Dayer; C Zavadil-Grob; C Ucla; B Mach
Journal:  Eur J Immunol       Date:  1984-10       Impact factor: 5.532

4.  Effect of indomethacin on increased resistance to bacterial infection and on febrile responses induced by muramyl dipeptide.

Authors:  M Parant; G Riveau; F Parant; C A Dinarello; S M Wolff; L Chedid
Journal:  J Infect Dis       Date:  1980-11       Impact factor: 5.226

5.  Inhibition of endogenous pyrogen-induced fever by a muramyl dipeptide derivative.

Authors:  M Parant; G Riveau; F Parant; L Chedid
Journal:  Am J Physiol       Date:  1984-09

6.  Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity.

Authors:  L A Chedid; M A Parant; F M Audibert; G J Riveau; F J Parant; E Lederer; J P Choay; P L Lefrancier
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

7.  Recombinant granulocyte-macrophage colony-stimulating factor down-regulates expression of IL-2 receptor on human mononuclear phagocytes by induction of prostaglandin E.

Authors:  W W Hancock; M E Pleau; L Kobzik
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

8.  Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse.

Authors:  M Parant; F Parant; L Chedid; A Yapo; J F Petit; E Lederer
Journal:  Int J Immunopharmacol       Date:  1979

9.  Edemagenic activity of aqueous form of muramyl dipeptide (MDP) in rats.

Authors:  Z Zídek; K Masek
Journal:  Methods Find Exp Clin Pharmacol       Date:  1985-08

10.  Adjuvant polyarthritis. V. Induction by N-acetylmuramyl-L-alanyl-D-isoglutamine, the smallest peptide subunit of bacterial peptidoglycan.

Authors:  Y H Chang; C M Pearson; L Chedid
Journal:  J Exp Med       Date:  1981-04-01       Impact factor: 14.307

View more
  2 in total

1.  The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells.

Authors:  E C Darcissac; M J Truong; J Dewulf; Y Mouton; A Capron; G M Bahr
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice.

Authors:  G M Bahr; E C Darcissac; N Castéran; C Amiel; C Cocude; M J Truong; J Dewulf; A Capron; Y Mouton
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.